- Home
- EDBL vs SILO Comparison
EDBL vs SILO Comparison
Compare EDBL & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDBL | SILO |
|---|---|---|
| Founded | 2020 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Apparel |
| Sector | Consumer Staples | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 4.5M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | EDBL | SILO |
|---|---|---|
| Price | $0.78 | $0.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 190.2K | 186.2K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,553,000.00 | $72,102.00 |
| Revenue This Year | $29.56 | $1.86 |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $0.33 |
| 52 Week High | $10.60 | $3.37 |
Technical Indicators
Market Signals| Indicator | EDBL | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 40.24 | 45.03 |
| Support Level | $0.48 | $0.33 |
| Resistance Level | $1.04 | $0.43 |
| Average True Range (ATR) | 0.14 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 29.93 | 48.67 |
Price Performance
Historical ComparisonAbout EDBL Edible Garden AG Incorporated
Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.